Assessing the Role of 21-Gene Assays in Breast Cancer

John H. Ward, MD, Margaret A. Amundsen Endowed Professor of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

Patients who have a low 21-gene recurrence score can be spared chemotherapy. It is predicted that 46% of women with breast cancer can forego chemotherapy, according to Ward.